Search Follow us

Threshold Pharmaceuticals (THLD)

Business description

Threshold is focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Ph III for STS and pancreatic cancer and earlier trials in other cancers. It is partnered with Merck KGaA.

A new threshold

QuickView | Pharmaceutical & healthcare | 03/07/2013

The TH-302 Phase III study in soft tissue sarcoma (STS) has been expanded to include another 170 patients. This reflects new assumptions about survival in the doxorubicin control arm and faster-than-expected enrolment, and maintains the trial power to detect a four-month survival benefit. Importantly, we expect a modest impact on trial timelines (three to six months) and expenditure (Merck KGaA contributes 70% of trial costs).

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.US$35.6m
Last closeUS$0.498
High / Low (52 weeks)US$1.3 / US$0.4
Stock market listingUS
Forecast net cash (US$m)31
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *24.2(4.6)(14.3)

* % Relative to local index

Company news